These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24362713)

  • 21. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
    Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
    Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
    Oishi T; Itamochi H; Kigawa J; Kanamori Y; Shimada M; Takahashi M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2007; 17(5):1040-6. PubMed ID: 17433067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
    Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
    Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
    Yang H; Yoon SJ; Jin J; Choi SH; Seol HJ; Lee JI; Nam DH; Yoo HY
    Biochem Biophys Res Commun; 2011 Mar; 406(1):53-8. PubMed ID: 21291864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
    Zabludoff SD; Deng C; Grondine MR; Sheehy AM; Ashwell S; Caleb BL; Green S; Haye HR; Horn CL; Janetka JW; Liu D; Mouchet E; Ready S; Rosenthal JL; Queva C; Schwartz GK; Taylor KJ; Tse AN; Walker GE; White AM
    Mol Cancer Ther; 2008 Sep; 7(9):2955-66. PubMed ID: 18790776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
    Liu B; Chen W; Li H; Li F; Jin X; Li Q
    Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
    Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.
    Hsu WH; Zhao X; Zhu J; Kim IK; Rao G; McCutcheon J; Hsu ST; Teicher B; Kallakury B; Dowlati A; Zhang YW; Giaccone G
    J Thorac Oncol; 2019 Jun; 14(6):1032-1045. PubMed ID: 30771522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
    Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
    J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
    Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
    Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
    Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
    Mabuchi S; Kawase C; Altomare DA; Morishige K; Sawada K; Hayashi M; Tsujimoto M; Yamoto M; Klein-Szanto AJ; Schilder RJ; Ohmichi M; Testa JR; Kimura T
    Clin Cancer Res; 2009 Sep; 15(17):5404-13. PubMed ID: 19690197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer.
    Huang HL; Chao MW; Li YC; Chang LH; Chen CH; Chen MC; Cheng CC; Liou JP; Teng CM; Pan SL
    Sci Rep; 2016 Aug; 6():31664. PubMed ID: 27526962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
    Ma Y; Cao H; Lou S; Shao X; Lv W; Qi X; Liu Y; Ying M; He Q; Yang X
    J Mol Med (Berl); 2015 Apr; 93(4):427-38. PubMed ID: 25411027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
    Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
    Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
    Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.